IDEAYA Biosciences, Inc.: Stifel resumes coverage with buy rating; price target $48
IDYA•Stifel resumed coverage of IDEAYA Biosciences with a buy rating and a $48 price target.
Related News
Visium Technologies extends exclusivity for proposed device rights transfer through March 2027
VISM•
Auna Q3 Peru healthcare capacity utilization rises to 89.2%
AUNA•
California Water Service Group prices $275 million in senior unsecured notes and first mortgage bonds
CWT•
Copper hits 10-day low on profit-taking as supply worries ease
XLB•
Penske Automotive rises after agreeing to be taken private by Penske, Mitsui
PAG•